Recent Updates
Recently added Catalysts
PRLD Positive Sentiment

Discovery and preclinical characterization of orally bioavailable JAK2V617F mutant selective JH2 inhibitors with disease modification potential in myeloproliferative neoplasms

Saturday, December 6, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the discovery and preclinical evaluation of novel JH2 inhibitors that selectively target the JAK2V617F mutant. These compounds exhibit potential for disease modification in myeloproliferative neoplasms and are designed to be orally bioavailable, which could enhance patient adherence to treatment. The research highlights the significance of these inhibitors in advancing therapeutic options.
Price reaction · baseline $1.46 (2025-12-05 close) · 1 other PRLD headline(s) in the window, move may be shared
day 0 close
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • Discovery of selective JH2 inhibitors shows promise for treatment.
  • Potential for disease modification in myeloproliferative neoplasms.
  • Orally bioavailable compounds may improve patient compliance.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+217%
120-day peak, hindsight
Typical move
8.2%
average across 4 past catalysts
Cash runway
~29 mo
Minimal dilution risk
Lead asset
PRT1419
Phase 1 · Multiple Myeloma

Full Press Release Details

Neha Bhagwat 1 , Duanya Liu 2 , Xiaowei Wu 1 , Alexander Grego 1 , Amy Crossan 1 , Andrew Moore 1 , Arpita Mondal 1 , Carly Bachner 1 , Dani Roth 1 , Diego Elrio, John Rose 1 , Joseph Rager 1 , Joy Cote 1 , Kirsten Gallagher 1 , Klare Bersch 1 , Miles Cowart 1 , Min Wang 1 , Natalie Kurtz 1 , Norman Fultang 1 , SharayuChandratre 1 , Song Mei 1 , Srijita Dhar 1 , Sushanta Ratna 1 , Stephanie Rodgers 1 , Yann Loret 1 , Yue Zou 1 , Sandy Geeganage 1 , Andrew Combs 1 , Jean-Jacques Kiladjian 2 , Stephane Giraudier 2 , Peggy Scherle 1

Frequently Asked Questions

What are JAK2V617F mutant selective JH2 inhibitors?

They are novel compounds designed to selectively inhibit the JAK2V617F mutant.

What potential do these inhibitors have?

They may offer disease modification in myeloproliferative neoplasms.

Why is oral bioavailability important?

Oral bioavailability can enhance patient compliance with treatment.

ShareAdd on Google
Tags: PRLD Viatris Investor Conferences Healthcare JAK2V617F JH2 inhibitors myeloproliferative neoplasms oral bioavailability disease modification
Last updated: Dec 6, 2025

Biotech snapshot

Cash runway
$152M liquidity · $5M/mo burn
~29 mo
Minimal dilution risk
Lead asset
PRT1419Phase 1
Multiple Myeloma →

Catalyst track record

+217%
best trade around PRLD's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PRLD.

See every catalyst's timing & PoA →